Acetylcholine

Brain Wafers™ Offer Novel Path to Increase Neurotransmitters for Brain and Body Energy

Thursday, October 14, 2021 - 1:38pm

Offering on-the-go energy for brain and body, Brain Wafers have natural ingredients that enhance the body's own production of excitatory neurotransmitters safely increasing mental and physical energy, along with providing mood and memory support.

Key Points: 
  • Offering on-the-go energy for brain and body, Brain Wafers have natural ingredients that enhance the body's own production of excitatory neurotransmitters safely increasing mental and physical energy, along with providing mood and memory support.
  • Neurotransmitters are natural brain chemicals that help transmit nerve impulses to other nerves and organs, often classified as either stimulating or inhibiting.
  • Brain Wafers have natural precursors for aiding the body in creating these neurotransmitters.
  • Nutrients from Brain Wafers are quickly and efficiently absorbed and used, giving a needed energy lift that starts in minutes."

Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance on all Primary and Secondary Endpoints, from Both U.S. Phase 3 Pivotal Clinical Studies of Sofpironium Bromide Gel, 15% in Primary Axillary Hyperhidrosis Patients

Thursday, October 7, 2021 - 11:55am

BOULDER, Colo., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, today announced positive topline results from the Phase 3 pivotal Cardigan I and Cardigan II studies, which evaluated sofpironium bromide gel, 15% as a once daily topical formulation in patients with primary axillary hyperhidrosis (excessive underarm sweating).

Key Points: 
  • Overall, 89% of patients who were randomized to sofpironium gel, 15% in the studies completed the full six weeks of treatment.
  • Five (2.9%) and nine (5.0%) subjects who received sofpironium bromide gel, 15%, discontinued the Cardigan I and II studies, respectively, due to a TEAE.
  • The dial-in number for the conference call is 1-877-705-6003 for domestic participants and 1-201-493-6725 for international participants, with Conference ID #13723931.
  • A live webcast of the conference call can be accessed here or through the Investors tab on the Brickell Biotech website at https://www.brickellbio.com .

Cerevel Therapeutics Hosts Virtual R&D Event to Review CVL-871 in Dementia-Related Apathy and Provide Update on CVL-231 for the Treatment of Schizophrenia

Thursday, October 7, 2021 - 12:00pm

CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, will host a virtual R&D event today from 10:00 to 11:30 a.m. ET. Presented in a live webcast format, Cerevel will discuss CVL-871, a dopamine D1/D5 receptor partial agonist in development for the treatment of dementia-related apathy, and provide an update on CVL-231, a muscarinic M4 positive allosteric modulator in development for the treatment of schizophrenia. This R&D event is one of a series of virtual webcasts dedicated to providing in-depth discussions on key portfolio programs.

Key Points: 
  • This R&D event is one of a series of virtual webcasts dedicated to providing in-depth discussions on key portfolio programs.
  • CVL-871 is currently being studied in a Phase 2a exploratory trial to evaluate the compound as a potential treatment for dementia-related apathy.
  • Cerevel received Fast Track designation for the development of CVL-871 in this indication from the U.S. Food and Drug Administration earlier this year.
  • The live webcast and accompanying presentation can be accessed on the investor relations section of the Cerevel Therapeutics website here .

Global Brain Health Supplements Market 2021-2029 - Key Players are Teva Pharma, Purelife Bioscience, Liquid Health, and HVMN Among Others - ResearchAndMarkets.com

Monday, September 27, 2021 - 10:40am

The global brain health supplement market is predicted to surge with rise in aging population and to combat neurological disorders.

Key Points: 
  • The global brain health supplement market is predicted to surge with rise in aging population and to combat neurological disorders.
  • It is anticipated that, brain health supplements industries would show significant market growth during forecast period.
  • North America is the largest regional market for brain health supplements accounting more than 54.8% of market share in 2020.
  • However, Europe is the expected to be the second largest regional market for brain health supplements, growth is mainly driven by the old and young population.

Cerevel Therapeutics to Host Virtual R&D Event on October 7

Friday, September 10, 2021 - 12:00pm

CAMBRIDGE, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will host a virtual R&D event on Thursday, Oct. 7 from 10:00 to 11:30 a.m. ET. Hosted in a live webcast format, Cerevel will lead a discussion focused on CVL-871, a D1/D5 partial agonist for dementia-related apathy, as well as provide an update on CVL-231, its M4 positive allosteric modulator in development for the treatment of schizophrenia. This R&D event is one of a series of virtual webcasts dedicated to providing in-depth discussions on key portfolio programs.

Key Points: 
  • ET
    CAMBRIDGE, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will host a virtual R&D event on Thursday, Oct. 7 from 10:00 to 11:30 a.m.
  • This R&D event is one of a series of virtual webcasts dedicated to providing in-depth discussions on key portfolio programs.
  • The live webcast can be accessed on the investor relations section of the Cerevel Therapeutics website here .
  • Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases.

TJ Nutrition® Announces Four Esteemed Professionals to Join Advisory Board

Thursday, September 9, 2021 - 2:00pm

As a patient of POTS Care, PLLC who has benefited from the support of TJ Nutrition products, Jesse has a personal connection to the work of TJ Nutrition.

Key Points: 
  • As a patient of POTS Care, PLLC who has benefited from the support of TJ Nutrition products, Jesse has a personal connection to the work of TJ Nutrition.
  • "I'm thrilled to serve on the medical advisory board for TJ Nutrition," Dr. Karpecki said.
  • The Advisory Board for TJ Nutrition will help disseminate this new knowledge and teach others how this approach can be dovetailed into their current evaluation and treatment regimen for dry eye.
  • TJ Nutrition is now at the forefront of unique, patented supplements based on her research through Genetic Disease Investigators.

Alpha Cognition Announces the Acceptance of its US FDA Investigational New Drug Application (IND) for Lead Candidate, ALPHA-1062 for Mild to Moderate Alzheimer’s Disease

Tuesday, September 7, 2021 - 2:00pm

The Company plans to initiate a Pivotal relative bioavailability study of ALPHA-1062, a proprietary, delayed release oral tablet formulation designed to treat mild to moderate Alzheimers Disease.

Key Points: 
  • The Company plans to initiate a Pivotal relative bioavailability study of ALPHA-1062, a proprietary, delayed release oral tablet formulation designed to treat mild to moderate Alzheimers Disease.
  • This single set of trials, if successful, will allow the company to submit a New Drug Application (NDA) for ALPHA-1062 in 2022.
  • We have engineered ALPHA-1062 with the goal of enhancing the desirable features of an AChEI while limiting the known liabilities.
  • The metabolite of Alpha-1062 is an approved drug (galantamine) to treat Alzheimers disease, and therefore qualifies for this shortened approval pathway.

Brickell Biotech Announces Final Patient Completed Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Monday, August 16, 2021 - 1:00pm

BOULDER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that the final patient has completed the Phase 3 pivotal Cardigan II study, which is evaluating sofpironium bromide gel, 15% in patients with primary axillary (underarm) hyperhidrosis. The Company expects to announce topline results for the U.S. Phase 3 pivotal Cardigan I and Cardigan II studies concurrently in the fourth quarter of 2021. Pending the outcome of these studies, the Company expects to submit a New Drug Application (NDA) for sofpironium bromide gel, 15% to the U.S. FDA in mid-2022.

Key Points: 
  • Were excited to announce that all patients have now completed their final visits in the Cardigan I and Cardigan II studies of sofpironium bromide gel, 15% in patients with primary axillary hyperhidrosis.
  • Phase 3 clinical program for sofpironium bromide gel, 15% is comprised of two pivotal clinical studies, Cardigan I and Cardigan II.
  • Each study has enrolled approximately 350 subjects nine years of age and older with primary axillary hyperhidrosis.
  • The studies are multicenter, randomized, double-blinded, vehicle (placebo)-controlled studies evaluating the efficacy and safety of topically applied sofpironium bromide gel, 15%.

Brickell Biotech Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Thursday, August 12, 2021 - 9:01pm

BOULDER, Colo., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Key Points: 
  • Research and development expenses were $8.8million for the second quarter of 2021, compared to $2.7million for the second quarter of 2020.
  • General and administrative expenses were $2.9million for the second quarter of 2021, compared to $3.0million for the second quarter of 2020.
  • Total other income, net was $0.4million for the second quarter of 2021, compared to $7thousand for the second quarter of 2020.
  • Brickells net loss was $11.1million for the second quarter of 2021 compared to $5.1million for the second quarter of 2020.

AEON Biopharma Announces the Appointment of Alex Wilson as General Counsel

Wednesday, August 11, 2021 - 12:05pm

NEWPORT BEACH, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for therapeutic indications, today announced the appointment of Alex Wilson to the role of General Counsel.

Key Points: 
  • NEWPORT BEACH, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for therapeutic indications, today announced the appointment of Alex Wilson to the role of General Counsel.
  • I am proud to join AEON at this exciting time in the companys history.
  • Prior to joining AEON, Alex served as Associate General Counsel, Business Development & Sustainability at Glaukos Corporation.
  • Previously, Alex worked as a corporate attorney in the Newport Beach office of OMelveny & Myers.